Company
Axsome Therapeutics
Axsome Therapeutics has 8 drugs tracked on RxWires: 2 post-market, 5 in Phase 3, 1 in Phase 2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| AXS-05 | Post-Market | Major Depressive Disorder |
| Solriamfetol | Post-Market | Excessive Daytime Sleepiness |
| AXS-07 (meloxicam-rizatriptan) | Phase 3 | Migraine |
| AXS-14 (Esreboxetine) | Phase 3 | Fibromyalgia |
| Solriamfetol Dose A | Phase 3 | ADHD |
| AXS-02 | Phase 3 | Osteoarthritis, Knee |
| AXS-12 (reboxetine) | Phase 3 | Narcolepsy |
| Dextromethorphan-Bupropion | Phase 2 | Major Depressive Disorder (MDD) |
Latest
- axsome therapeutics filed 8-K
- axsome therapeutics filed 8-K
- axsome therapeutics filed 8-K
- axsome therapeutics filed 8-K
- axsome therapeutics filed 8-K
Follow Axsome Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.